Startup profile for Adaptyv: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Adaptyv funding, valuation and investors

YC S21 automated wet lab that synthesizes and tests AI-designed proteins and returns experimental data.

Keep track of Adaptyv

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$40M · August 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$48M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · Lausanne, Switzerland (Biopôle / Épalinges)

Investors in latest funding

Lead: Highland Europe

Other: Y Combinator , ACE Ventures , byFounders

Sources: latest funding Last verified: 2026-08-31

Overview

Adaptyv Bio (Adaptyv Biosystems) is a Lausanne company building an automated protein foundry so researchers and AI agents can submit sequences and get wet-lab measurements back. Y Combinator lists it in the Summer 2021 batch. On August 25, 2026 it announced a $40 million Series A led by Highland Europe; ACE Ventures, byFounders, and Y Combinator participated. The company post cites more than 5x lab throughput growth over the prior year and more than 100 customers, including bio-AI labs Chai Discovery and Boltz and pharmas Roche and Novo Nordisk. It also describes a collaboration in which Anthropic’s Claude designed proteins that were tested in Adaptyv’s lab. Valuation and revenue were not disclosed in that post. ACE Ventures led an $8 million seed dated September 25, 2025 on ACE’s own site. Highland Europe, ACE Ventures, and byFounders do not have Venture Capital Tracker /fund/ pages; Y Combinator does.

Why Adaptyv is interesting

August 25, 2026: $40M Series A led by Highland Europe with YC, ACE Ventures, and byFounders returning. No valuation. Company names Chai Discovery, Boltz, Roche, and Novo Nordisk among 100+ customers and says lab throughput grew more than 5x in a year.

Product & use cases

Automated wet lab and API for synthesizing and testing designed proteins, so AI design loops can close against physical measurements rather than in-silico scores alone.

  • AI biology labs validating designed binders
  • Pharma groups that want faster binding measurements than an in-house 20-designs-per-target lab
  • Agent-submitted experiments via API (company)

Key facts

  • Aug 25, 2026: $40M Series A; Highland Europe lead; YC / ACE / byFounders returning; no valuation
  • YC Summer 2021; Lausanne automated protein lab
  • Company: >5x throughput; >100 customers; names Chai Discovery, Boltz, Roche, Novo Nordisk
  • Prior: $8M seed led by ACE Ventures (ACE post Sep 25, 2025)
  • No /fund/ pages for Highland Europe, ACE Ventures, or byFounders

Funding history (newest first)

Series A

2026-08 $40M

Source: https://www.adaptyvbio.com/blog/series-a

Seed

2025-09 $8M
  • ACE Ventures (lead)
  • byFounders (participant)

Source: https://aceventures.vc/ace-ventures-leads-8m-seed-round-in-adaptyv-bio-to-accelerate-the-future-of-protein-design/

Investors in our directory

Funds linked from Adaptyv's profile — open a fund page for stage focus and related deal articles.

Y Combinator

Competitive landscape

Edge: A disclosed Series A that prices lab capacity, not a therapeutic asset — plus named model-lab and pharma customers on the company post. That is an infrastructure signal, not a drug.

Adaptyv is a Series A bet that AI protein design is already faster than most wet labs, so the scarce asset is copyable automated workcells. Diligence is utilization and contract quality — not a valuation, which was not disclosed.

  • Chai Discovery adjacent

    Customer on Adaptyv’s Series A post. Chai sells molecular-design models ($400M Series C at $3.8B, July 2026). See /2026-chai-discovery-400m-series-c-index-sequoia.

  • Boltz adjacent

    Customer on Adaptyv’s Series A post. MIT-origin protein AI PBC. See /startup/boltz.

  • AusperBio adjacent

    Same-month nine-figure therapeutics print ($120M Series C). Drug company, not a lab. See /startup/ausperbio.

Notable stories

  • The August 25, 2026 company post names Chai Discovery and Boltz as customers. Those are company-named logos, not disclosed contract values.
  • ACE Ventures dates the $8M seed to September 25, 2025. Some August 2026 recaps say late 2024 — do not overwrite ACE’s date without a company correction.

Industries

Biotech & Life Sciences AI & Machine Learning

Related funding articles

Venture Capital Tracker pieces that cover Adaptyv's financing or category context.

FAQs about Adaptyv

Practical answers founders, operators, and investors typically search for.

$40 million Series A announced August 25, 2026. Valuation was not disclosed.
Highland Europe led. Y Combinator, ACE Ventures, and byFounders returned. Only YC has a /fund/ page here.
Yes. Y Combinator lists Adaptyv in Summer 2021.
An automated wet lab for synthesizing and testing designed proteins.
No.
No. Private Series A as of August 31, 2026.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.